Quick Takeaways
- Fairmount Funds Management LLC filed SCHEDULE 13D/A for Jade Biosciences, Inc. Common Stock, $0.0001 par value (JBIO).
- Disclosed ownership: 20%.
- Date of event: 06 Oct 2025.
Quoteable Key Fact
"Fairmount Funds Management LLC disclosed 20% ownership in Jade Biosciences, Inc. Common Stock, $0.0001 par value (JBIO) on 06 Oct 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original Filing| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | 20% | 10,353,875 | 0 | 10,353,875 | /s/ Peter Harwin | Peter Harwin, Managing Member | 0001802528 |
| Fairmount Healthcare Fund II L.P. | 15% | 7,698,058 | 0 | 7,698,058 | /s/ Peter Harwin | Peter Harwin, Managing Member | 0001769651 |
| Fairmount Healthcare Co-Invest IV L.P. | 5.8% | 2,655,817 | 0 | 2,655,817 | /s/ Peter Harwin | Peter Harwin, Managing Member | 0002042283 |
| Peter Evan Harwin | 20% | 10,353,875 | 0 | 10,353,875 | /s/ Peter Harwin | Peter Harwin | 0001663607 |
| Tomas Kiselak | 20% | 10,353,875 | 0 | 10,353,875 | /s/ Tomas Kiselak | Tomas Kiselak | 0001830177 |